Impact of Gene Polymorphisms, Platelet Reactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Abstract

In clopidogrel-treated patients with NSTEACS undergoing PCI, HPR was independently associated with an increased risk of MACE only in the presence of a high SS.

Genotype Frequencies of CYP2C19, P2Y₁₂ and GPIIIa Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness

“…Our results are in agreement with those reported by earlier studies. [29][30][31] Interestingly, no patient was wild type and heterozygous for CYP2C19 * 3. In addition, the number of heterozygous patients for CYP2C19 * 17 was also rare.…”

Impact of CYP2C19 Variants on Clinical Efficacy of Clopidogrel and 1-Year Clinical Outcomes in Coronary Heart Patients Undergoing Percutaneous Coronary Intervention

“…Over several decades, the ADP-induced optical turbidimetric platelet aggregation assay, the traditional “gold standard” method to detect platelet function, has been employed to evaluate the antiplatelet efficacy of clopidogrel. However, in studies using this platelet function test, cutoff values for high on-treatment platelet reactivity established via receiver operating characteristic curve analysis were variable (Palmerini et al, 2014). A number of studies used other measures, such as SYNTAX score or platelet reactivity index, to investigate associations with risk of mortality, myocardial infarction and ST in patients with non–ST segment elevation acute coronary syndrome undergoing PCI (Palmerini et al, 2011, 2014).…”

“…However, in studies using this platelet function test, cutoff values for high on-treatment platelet reactivity established via receiver operating characteristic curve analysis were variable (Palmerini et al, 2014). A number of studies used other measures, such as SYNTAX score or platelet reactivity index, to investigate associations with risk of mortality, myocardial infarction and ST in patients with non–ST segment elevation acute coronary syndrome undergoing PCI (Palmerini et al, 2011, 2014). Clopidogrel blocks the platelet ADP receptor to inhibit platelet aggregation, in turn reducing expression of sCD40L and P-selectin and releasing them from platelets to prevent further platelet activation (Blake and Ridker, 2001; Steinhubl et al, 2002; Conde and Kleiman, 2003; Azar et al, 2006).…”

Is the Syntax Score Sufficient to Assess the Risk for Patients Undergoing Elective Percutaneous Coronary Interventions?

“…В исследовании GEPRESS (2014) [13] определение ОРТ в когорте 1053 больных ОКС позволяло получить дополни-тельную прогностическую информацию с…”